






Indian pharmaceutical companies are navigating a “reset,” moving from low-margin generic manufacturing to high-value areas like biologics, novel drug discovery, and complex specialty products, with a goal of becoming a $450–500 billion industry by 2047.
The obesity drug market is seeing intense activity, with 2026 acting as a pivotal year for GLP-1 and amylin therapies (like Novo Nordisk’s CagriSema) in India, potentially turning diabetes management into a major growth driver.
Pharma Growth 2026: Explore how Indian pharmaceutical industry is positioning itself for future growth through innovation
If your facility handles hazardous, toxic, or potent dusts, a BIBO dust collector is the safest and most compliant solution. It ensures worker protection, environmental safety, and regulatory compliance, all while maintaining efficient dust collection performance.